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Evidence of the association between blood transfusions and its impact on prognostic
outcomes in patients who undergo curative resection of colorectal cancer remains
controversial. The aim of this study was to determine whether receiving peri-operative
blood transfusions during curative colorectal cancer resection affected overall survival,
cancer-related survival, and cancer recurrence. This retrospective study was undertaken
at The Royal Brisbane and Women’s Hospital, Australia, between 1984 and 2004. The
outcomes of 1370 patients undergoing curative colorectal cancer resection for TNM stage
I to III were analyzed. Four hundred twenty three patients (30.9%) required transfusion
and 947 patients (69.1%) did not. Peri-operative transfusion was associated with higher
rates of cancer recurrence on multivariate analysis (P¼0.024, RR, 1.257, 95% CI, 1.03–1.53);
however, it was not independently associated with poorer overall or cancer-related
survival. Where the aim is curative resection, this study contributes to a body of evidence
that blood transfusions may be associated with poorer outcomes.
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 Transfusion
Colorectal cancer (CRC) is the third most com-mon cancer and the most frequent cancer
presenting in the elderly.1 Each year there are
almost 1 million new cases and 500,000 deaths from
colorectal cancer worldwide.1 Colorectal cancer is a
common cause of anemia, contributing to a higher
incidence of perioperative blood transfusions in
these patients.2 Peri-operative blood transfusions
ranging from 10%68% have been reported for
patients undergoing colorectal cancer resection.3
Blood transfusions have been associated with tumor
recurrence and poorer survival through immuno-
modulation, with many theories of the mechanisms
presented in the current literature.
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A literature review was conducted and 11
relevant studies analyzed (see Table 1).315 Current
findings in the literature remain controversial. While
most studies agree that nontransfused patients had
better outcomes, the magnitude of the association of
immunomodulation to blood transfusions, and
whether the association is a causal one, remains
speculative. Thus there is still impetus to establish
whether any concrete causal relationship exists.
This is, to our knowledge, the largest study to
date, which aims to determine whether receiving
perioperative blood transfusions during curative
colorectal cancer resection impacts overall survival,
cancer-related survival, and cancer recurrence, as
well as the independent outcome predictors.13
Materials and Methods
Patients
Data were prospectively collated on a computerized
database from the records of 1370 patients undergo-
ing curative colorectal cancer treatment at the
Department of Surgery, Royal Brisbane and Women’s
Hospital, between 1984 and 2004. Informed consent
from patients, and approval from the Royal Brisbane
and Women’s Hospital ethics committee was ob-
tained. The Tumour Node Metastasis (TNM) classifi-
cation system was used to stage patients. All patients
with stage I to III colorectal cancer who underwent
curative resection were included in this study.
Data collection
Data was collected for age (70 years, ,70 years);
sex; pre-operative hemoglobin level (,12 g/L, 12
g/L); tumor site (right: cecum to distal transverse
colon, left: splenic flexure to distal rectum); tumor
size (.7 cm, 7 cm); tumor type (mucinous, non-
mucinous); nodal involvement (N0, N1); tumor
grade (poor, well to moderate); TNM stage (0, 1, 2,
3); procedure category (urgent, elective); surgical
complications, medical complications, need for reop-
eration, and when transfusion occurred (intra-oper-
ative, postoperative, peri-operative). Blood
transfusion data was obtained from patient records.
Patients were considered to have had a blood
transfusion if they received any blood product
during hospitalization before, during, or after sur-
gery. Anemia was defined by a preoperative hemo-
globin level of ,12 g/L. The indication for receiving
a transfusion at any time during hospitalization
varied and was dependent on individual physiologic
reserve. Procedures were considered urgent if un-
dertaken outside of the routine elective colorectal or
general surgery operating lists. Surgical complica-
tions included wound infections and dehiscence,
paralytic ileus, obstruction, anastomotic leakage, and
infective diarrhea that occurred within 30 days of
surgery. Medical complications included cardiac
arrest, arrhythmias, postoperative heart failure, acute
coronary syndrome, pneumonia, pleural effusion,
acute respiratory distress syndrome, urinary tract
infection, urinary retention, and urinary incontinence
that occurred within 30 days of surgery.
Survival
Overall survival was defined as the duration of time
from curative resection to death from any cause.
Cancer-related survival was defined as the duration
Table 1 Studies evaluating the association between survival, recurrence, and receiving blood transfusions during colorectal cancer resection
Authors Year Study size
Overall survival:
6 Significant
5 Not significant
Cancer-related survival:
4 Significant
5 Not significant
Recurrence:
5 Significant
4 Not significant
Due 2012 855 Not significant Significant Not evaluated
Skanberg 2007 640 Significant Significant Not evaluated
Nursal 2006 812 Significant Not significant Significant
Miki 2006 117 Significant Not evaluated Not evaluated
Jagotidsch 2006 885 Not significant Not significant Not significant
Mynster 2001 740 Not significant Not significant Not significant
van de Watering 2001 697 Significant Not evaluated Not significant
Houbiers 1994 871 Significant Not significant Not significant
Heiss 1994 30 Not evaluated Not evaluated Significant 2 times greater risk
Busch 1993 423 Not significant Not significant Not evaluated
Chung (meta-analysis) 1993 5236 Not significant Significant Significant
Tang 1993 725 Significant Significant Significant
Tartter 1992 339 Not evaluated Not evaluated Significant dose-related effect
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of time from curative resection to death from cancer.
The patient follow up protocol consisted of 3
monthly reviews for the first 2 years after surgery,
then 6 monthly reviews for the next 3 years, and
yearly thereafter. Patients were followed up until
death or until lost to followup.
Recurrence
Recurrence or disease-free survival was defined as
the duration of time that the patient was disease
free, from the time of resection to recurrence.
Patients were followed up until recurrence, death,
or lost to followup. Recurrence was monitored by
carcino-embryonic antigen (CEA) levels, radiologic
imaging, and colonoscopy or proctosigmoidoscopy
as clinically indicated, and at intervals recommend-
ed by the National Health and Medical Research
Council (NHMRC) and Australia’s Cancer Council
Clinical Guidelines for each stage of cancer.
Statistical Analysis
Data from 1370 patients who underwent curative
colorectal cancer surgery were analyzed using
univariate and multivariate analyses to identify
factors significantly associated with overall survival,
cancer-related survival, and disease-free survival.
All data was displayed as categoric variables only.
Chi squared (Fisher exact and Pearson’s) testing was
used to compare transfused and nontransfused
groups and predicted prognostic factors. A P value
of ,0.05 was considered statistically significant. The
Kaplan-Meier model and log rank test was used for
univariate analysis of the outcome measures. Five
year and median survival probabilities were record-
ed. The Cox regression model was used for
multivariate survival analysis. The logistic regres-
sion model was used to determine independent
predictors of survival and recurrence. Forward and
backward regression analysis of variables identified
those with a P value ,0.05 and these formed the
provisional model. Remaining variables were re-
entered into the model as potential confounders. A
confounding variable was defined as one where the
estimate changed by 10%. Factors found to be
significant were assessed for 2-way interactions.
Independent prognostic significance was presented
as a relative risk (RR) with 95% confidence intervals.
All statistical evaluations were conducted using the
PASW statistics version 19.0 (2010 SPSS Inc; IM,
Chicago, IL).
Results
Patients and tumor characteristics
Of the 1370 patients who received curative
surgery for stage I to III colorectal cancer, 423
patients (30.9%) required transfusion and 947
patients (69.1%) did not. Characteristics of the
transfused and nontransfused groups are listed
and compared in Table 2, and shows that the two
groups were well matched for demographics and
cancer-related characteristics: 44.4% of transfused
patients and 27.7% of nontransfused patients had
1 or more surgical complications (P , 0.001), and
24.3% of transfused patients and 13.8% of non-
transfused patients had 1 or more medical
complications (P , 0.001). More reoperations were
required (13.2%) during the same admission for
transfused patients compared to nontransfused
patients (4.8%; Table 2).
Recurrence
Peri-operative blood transfusions were indepen-
dently associated with earlier cancer recurrence.
This result remained significant even when sub-
classifying patients according to whether they had
a transfusion pre-operatively, intra-operatively or
postoperatively. Overall peri-operatively, 63.8% of
patients in the transfused group and 68.6% in the
non-transfused group developed recurrence at 5
years (P ¼ 0.024) [see Table 3]. Preoperative
hemoglobin was not associated with poorer disease
free survival. Multivariate analysis found that sex,
stage, lymph node involvement, grade, urgency of
procedure, reoperation, perioperative transfusion
including postoperative and intraoperative trans-
fusions, were also independently related to recur-
rence.
Overall survival
On univariate analysis the overall survival was
35.2% in the transfused patients, and 43.8% in the
nontransfused patients (P ¼ 0.001; Table 4). Multi-
variate analysis found that age, sex, stage, lymph
node involvement, grade, urgency of procedure,
medical complications, reoperation, and intra-oper-
ative transfusion were all independently related to
overall survival. Intraoperative transfusion recipi-
ents had a median survival time of 50 months while
those who were not transfused or transfused at a
different time had a median survival time of 78 and
77 months respectively. This was found to be
statistically significant on multivariate analysis (RR
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¼ 1.31, P ¼ 0.004). Pre-operative hemoglobin, peri-
operative transfusion, postoperative transfusion,
and number of units transfused were not found to
be significantly associated with overall survival on
multivariate analysis.
Cancer-related survival
On univariate analysis the cancer-related survival in
transfused and nontransfused patients was 69.7%
and 73% respectively (P ¼ 0.051; Table 5). Multivar-
iate analysis found that sex, stage, lymph node
involvement, grade, urgency of procedure, medical
complications, and intra-operative transfusion were
independently associated with cancer-related sur-
vival. Pre-operative hemoglobin, peri-operative
transfusion, postoperative transfusion, age, and re-
operation, were not found to be significantly
associated with cancer-related survival on multivar-
iate analysis.
Discussion
Transfusing patients peri-operatively for curative
colorectal cancer resection is often done based on
immediate clinical and biochemical indicators, with
the aim of resuscitation and decreasing peri-opera-
tive mortality and morbidity. The indications for
blood transfusions have been well established in the
literature and include acute or subacute hemor-
rhage, severe anemia, hemolytic crisis, as well as
applying good clinical judgment.2,7,16 However, the
impact of the transfusion on the patient’s cancer-
related prognosis might not be considered or
discussed with the patient.
This is one of the largest studies to date and
supports a growing body of evidence suggesting
that peri-operative transfusions potentially have a
negative impact on cancer related outcomes, partic-
ularly cancer recurrence. This finding is important,
as alternative resuscitation methods and earlier
preoperative optimization may need to be consid-
ered more carefully in patients with colorectal
cancer.16 Closer followup protocols may need to be
considered in transfused patients.
Blood transfusions have been associated with
tumor recurrence and poorer survival possibly due
to immunologic factors and have been termed
transfusion-related immunomodulation.17,18 The
current literature offers numerous theories as to
the exact mechanism of this immunomodulatory
effect. Figure 1 summarizes the cell-mediated
processes and humoral components involved. Most
studies conclude that host down-regulation of
immune function by blood transfusion allows
cancer cells to escape the immune surveillance
system causing micrometastases and recurrence,
which then impacts the clinical course of the
disease.19
Table 2 Characteristics of 947 nontransfused and 423 transfused
patients—Chi squared test
Variable
Nontrans-
fused %
Transfused
% P value
Age
.70 (1) 43.9 48.0 0.177
,70 (0) 56.1 52.0
Sex
Male (1) 52.8 47.2 0.218
Female (0) 43.5 56.5
Pre-operative hemoglobin
.12 (0) 66.3 56.9 0.001
,12 (1) 33.7 43.1
Tumor site
Right (0) 40.7 35.7 0.093
Left (1) 59.3 64.3
Tumor size
.7 cm (1) 49.7 44.8 0.126
,/¼7 cm (0) 50.3 55.2
Tumour Type
Mucinous 84.2 15.8 0.808
Nonmucinous 84.8 15.2
Lymph node
N0 (0) 67.1 64.3 0.323
N1, N2 (1) 32.9 35.7
Grade
Poor (1) 12.2 16.1 0.059
Well/moderate (0) 87.8 83.9
Stage
0 1.2 1.2 0.772 (Pearson)
1 18.7 18.6
2 47.7 45.1
3 32.4 35.2
Urgency
Elective 82.4 85.3 0.183
Emergency 17.6 14.7
Surgical complications
Yes 27.7 44.4 ,0.001
No 72.3 55.6
Medical complications
Yes 13.8 24.3 ,0.001
No 86.2 75.7
Re-operation
Yes 4.8 13.2 ,0.001
No 95.2 86.8
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The studies listed in Table 1 have evaluated the
effects of perioperative blood transfusions on patients
with colorectal cancer,315 9 studies5,711,1315 assessed
the effect of blood transfusions on cancer recurrence
and 5 studies5,11,1315 found that it was significant.
However, only 7 of these studies5,710,14,15 used
multivariate analysis and of these studies, 3 found
an independent association5,14,15 (Table 6). Eleven
studies3–10,12–14 tested the impact of blood transfu-
sions on overall survival. Of these, 6 studies4–6,9,10,14
found an independent association (Table 1).
We found that peri-operative blood transfusions
were significantly associated with poorer overall
survival on univariate alone. Its loss of significance
on multivariate analysis suggests that the impact on
survival is likely a result of confounding factors.
Table 3 Factors related to recurrence in patients with stage I to III colorectal cancer
Parameter
Patients (died) Univariate analysis Multivariate analysis
(tf) n 5 yra Medianb P value RR 95% CI P value
Age
.70 (1) 66.4 63.1 120
,70 (0) 68.4 65.4 133 0.331 NS
Sex
Male 65.3 60.8 101
Female 69.7 67.9 200 0.006 1.253 1.0371.514 0.019
Preoperative Hemoglobin
.12 66.8 63.5 120
,12 68.9 66.2 0.348 NS
Stage
Stage 3 48.6 44.6 46
Stage 12 76.7 74.6 0.000 1.707 1.2102.407 0.002
Lymph node
N1, N2 (1) 48.6 44.6 46
N0 (0) 76.7 74.6 0.000 2.182 1.7912.659 0.000
Grade
Poor (1) 57.4 56.2 89
Well/Mod (0) 68.8 65.5 200 0.000 1.378 1.0771.763 0.011
Urgent
Yes (Emergency) 57.1 49.0 57
No (Elective) 69.3 67.1 161 0.000 1.428 1.1351.797 0.002
Medical complications
Yes 64.9 52.7 88
No 67.8 66.2 141 0.002 NS
Re-operation
Yes 54.9 44.5 49
No 68.3 65.6 133 0.000 1.632 1.1952.229 0.002
Intra-op transfusion
Yes 60.2 55.8 103
No 68.2 65.8 133 0.017 1.372 1.0681.763 0.013
Peri-op transfusion
Yes 63.8 58.9 103
No 68.6 66.8 133 0.012 1.257 1.0301.533 0.024
Postop transfusion
Yes 63.9 57.1 88
No 68.0 66.2 133 0.017 1.272 1.0141.594 0.037
NS, not significant.
a5-year Kaplan-Meier survival probability.
bmedian survival time.
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This suggests that the phenomenon could be due to
the circumstances that necessitate transfusion rather
than the transfusion itself. Tatter et al (1992) found a
more significant association as the number of units
transfused increased; however, this study did not
find any significant ‘‘dose-related association.’’15
Nine studies evaluated the effect of blood transfu-
sion on cancer-related survival and 4 of these found
an association; however, only 2 of these were
multivariate analysis.35,7,8,10,1214
Table 4 Factors related to overall survival in patients with stage I to III CRC
Parameter
Patients (died) Univariate analysis Multivariate analysis
(tf) n 5 yra Medianb P value RR 95% CI P value
Age
.70 (1) 35.3 48.0 55 ,0.001 1.82 1.572.10 ,0.001
,70 (0) 25.7 63.7 93
Sex
Male 33.6 51.5 62 0.004 1.31 1.131.51 ,0.001
Female 27.4 61.6 80
Pre-op Hb
.12 (normal) 36.1 58.7 77 0.008 NS
,12 24.5 52.6 64
Stage
Stage 3 31.6 42.3 47 ,0.001 1.45 1.251.67 ,0.001
Stage 12 46.3 63.6 85
Lymph node
N1, N2 (1) 24.1 42.6 47 ,0.001 1.44 1.251.67 ,0.001
N0 (0) 37.0 63.7 85
Grade
Poor (1) 9.6 45.4 48 ,0.001 1.34 1.111.63 0.003
Well/moderate (0) 51.2 58.0 76
Urgent
Yes (Emer) 11.2 45.7 50 ,0.001 1.30 1.081.56 0.006
No (Elec) 49.9 58.3 77
Medical complications
Yes 27.4 35.4 39 ,0.001 1.63 1.371.95 ,0.001
No 44.3 60.8 80
Re-operation
Yes 5.5 37.1 39 ,0.001 1.37 1.071.75 0.014
No 55.5 57.8 74
Peri-op transfusion
,4 units (0) 38.8 60.0 78 0.001 NS
.4 units (1) 20.0 48.6 57
Intra-op transfusion
Yes 30.1 48.4 50 0.012 1.31 1.091.59 0.004
no 42.9 57.7 74
Postop transfusion
Yes 37.9 45.4 53 0.004 NS
No 42.0 59.3 77
Peri-op transfusion
Yes 35.2 48.6 57 0.001 NS
No 43.8 60.0 78
NS, not significant.
a5-year Kaplan-Meier survival probability.
bmedian survival time.
SURVIVAL AND RECURRENCE IN STAGE I TO III COLORECTAL CANCER TALUKDER
Int Surg 2014;99 13
Complications were higher in the transfused
group, and this is consistent with most other
studies.3,5,79 The fact that some studies have found
postoperative infections to increase with postoper-
ative transfusions only, has led to suggestions that
the effect of transfusions is short term as well as
long term with recurrence.4,5,7,8,12 One study found
that preoperative transfusion did not increase
wound infections after elective colorectal resection;
however, this may not apply to this study’s sample
as preoperative transfusion was associated with
lower preoperative hemoglobin and overall poorer
physiologic reserve.5 Mystner et al (2000) found that
transfusions were not significantly associated with
Table 5 Factors related to cancer related survival in patients with stage I to III colorectal cancer
Parameter
Patients (died) Univariate analysis Multivariate analysis
(tf) n 5 yra Medianb P value RR 95% CI P value
Age
.70 (1) 71.7 68.5 202
,70 (0) 72.3 71.2 163 0.565 NS
Sex
Male 69.4 66.6 111
Female 75.2 73.8 200 0.001 1.338 1.0891.644 0.006
Pre-operative hemoglobin
.12 72.2 70.5 163
,12 72.6 69.9 0.848 NS
Stage
Stage 3 53.4 49.7 58
Stage 12 81.4 81.1 240 ,0.001 1.783 1.2042.640 0.004
Lymph node
N1, N2 (1) 53.4 49.7 58
N0 (0) 81.4 81.1 240 ,0.0001 2.458 1.9823.047 0.000
Grade
Poor (1) 60.0 57.9 89
Well/mod (0) 73.8 71.9 200 0.000 1.568 1.2112.030 0.001
Urgent
Yes (Emergency) 62.9 57.6 86
No (Elective) 73.8 72.4 200 0.000 1.425 1.1101.829 0.005
Medical complications
Yes 68.5 57.3 99
No 72.8 72.3 199 0.000 1.570 1.2182.025 .001
Re-operation
Yes 62.4 57.2 96
No 72.8 71.0 199 0.003 NS
Intra-op transfusion
Yes 65.9 60.9 133
No 73.0 71.7 199 0.030 1.338 1.0191.756 0.036
Peri-op transfusion
Yes 69.7 63.7 200
No 73.0 73.1 163 0.051 NS
Postop transfusion
Yes 70.2 62.1 200
No 72.5 72.3 199 0.084 NS
NS, not significant.
a5-year Kaplan-Meier survival probability.
bmedian survival time.
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reduced survival, but were significantly associated
with recurrence, and attributed this mainly to the
association between transfusions and postoperative
infections.8 A fatal infectious complication is anas-
tomotic failure, which can also lead to poorer
survival and recurrence and has been included in
this study as an unmeasured outcome as part of the
surgical complications.
Limitations of this study include retrospective
data and inclusion of patients between a 20-year
period during which time blood product process-
ing has markedly changed. Blood products are now
mostly separated rather than pooled, have better
infection screening, and superior cross-matching
technology. Changing surgical technique and stan-
dards of practice over time must also be consid-
ered. Randomization is not possible between
transfused and nontransfused patients and there-
fore selection bias will always exist. Survival
outcomes based on the type of blood product given
were not analyzed as some patients would have
received whole blood during the earlier years of
this study.
Conclusion
In conclusion, peri-operative blood transfusion in
this study was found to increase the likelihood of
colorectal cancer recurrence but was not found to
be associated with overall survival or cancer-
related survival. This study contributes to a body
of evidence that blood transfusions may be
associated with poorer outcomes and recurrence,
and is significant enough to indicate caution.
Where the aim is curative resection of colorectal
cancer, this study emphasizes the importance of
administering blood products with discretion and
after considering the short and long-term risks
and benefits.
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